Verona Pharma PLC
NASDAQ:VRNA
Intrinsic Value
Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. [ Read More ]
The intrinsic value of one VRNA stock under the Base Case scenario is 32.9 USD. Compared to the current market price of 15.47 USD, Verona Pharma PLC is Undervalued by 53%.
Valuation Backtest
Verona Pharma PLC
Run backtest to discover the historical profit from buying and selling VRNA stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Verona Pharma PLC
Current Assets | 289.7m |
Cash & Short-Term Investments | 271.8m |
Receivables | 11m |
Other Current Assets | 7m |
Non-Current Assets | 18.4m |
Long-Term Investments | 15m |
PP&E | 2.9m |
Intangibles | 545k |
Current Liabilities | 8.7m |
Accounts Payable | 3.5m |
Accrued Liabilities | 4.8m |
Other Current Liabilities | 435k |
Non-Current Liabilities | 50.1m |
Long-Term Debt | 48.4m |
Other Non-Current Liabilities | 1.8m |
Earnings Waterfall
Verona Pharma PLC
Revenue
|
0
USD
|
Operating Expenses
|
-67.6m
USD
|
Operating Income
|
-67.6m
USD
|
Other Expenses
|
13.2m
USD
|
Net Income
|
-54.4m
USD
|
Free Cash Flow Analysis
Verona Pharma PLC
VRNA Profitability Score
Profitability Due Diligence
Verona Pharma PLC's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Verona Pharma PLC's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
VRNA Solvency Score
Solvency Due Diligence
Verona Pharma PLC's solvency score is 74/100. The higher the solvency score, the more solvent the company is.
Score
Verona Pharma PLC's solvency score is 74/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VRNA Price Targets Summary
Verona Pharma PLC
According to Wall Street analysts, the average 1-year price target for VRNA is 34.53 USD with a low forecast of 31.31 USD and a high forecast of 39.9 USD.
Ownership
VRNA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
VRNA Price
Verona Pharma PLC
Average Annual Return | 66.05% |
Standard Deviation of Annual Returns | 124.7% |
Max Drawdown | -70% |
Market Capitalization | 1.3B USD |
Shares Outstanding | 80 983 904 |
Percentage of Shares Shorted | 8.46% |
VRNA News
Last Important Events
Verona Pharma PLC
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Verona Pharma PLC
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. The firm's product candidate, ensifentrine, is an investigational, inhaled, dual inhibitor of the enzyme's phosphodiesterase 3 and 4 (PDE3 and PDE4), which is designed to act as both a bronchodilator and an anti-inflammatory agent. The firm is developing ensifentrine in three formulations for mostly used inhalation devices, such as nebulizer, dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The company is evaluating nebulized ensifentrine in a Phase III clinical program ENHANCE (Ensifentrine as an inhaled nebulized chronic obstructive pulmonary disease (COPD) therapy) for COPD maintenance treatment. Verona Pharma, Inc. is its wholly owned subsidiary.
Contact
IPO
Employees
Officers
The intrinsic value of one VRNA stock under the Base Case scenario is 32.9 USD.
Compared to the current market price of 15.47 USD, Verona Pharma PLC is Undervalued by 53%.